Wednesday, July 24, 2013 7:16:15 AM
Projected Milestones for 2013
From the NNVC - RedChip video, the following are events and the projected Milestones for 2013:
-Completion of new Company cGMP/R&D Center in Shelton, CT
-Commission new cGMP plant and begin production of cGMP drugs
-Receive initial results of toxicology studies on FluCide TM
-Prepare IND for submission to regulatory authorities
I'm sure the Project Management group as well as the company that designed the toxicology and safety pharmacology studies were on board with these projected Milestones for 2013. Their reputation is on the line. I believe they will deliver. Company’s survival is dependent on reaching milestones efficiently (in terms of time and money) to successfully raise additional funding. The company has enough money to take them through Phase I/II 2014. How can they achieve the important Phases I/II if the projected Milestones are delayed? Yes, these Milestones are very important and they know it. We know it. Every time we post these news we are holding them accountable and the company is fully aware of that.
Other coming events in 2013:
Patents issued in Australia, Japan, China, the United States and in all of Africa. Twenty five countries thus far. Well over 100 countries should approve patent applications by the end of 2013. These patents were issued as "first in class" with no existing prior art.
I do expect application for DengueCide® orphan status will get approval from regulatory body ~ 2013
Having completed the expected 2013 projected Milestones and others, they will enter a controlled race to Phase I (2014). Anticipation will build and that will be good for all.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM